Allworth Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Allworth Financial’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6	Closed	–	–	3240
2022 Q3	$0	Buy	+6	New	+$220	﹤0.01%	3186
2022 Q2	–	Sell	-172	Closed	-$9K	–	2901
2022 Q1	$9K	Hold	172	–	–	﹤0.01%	1528
2021 Q4	$9K	Buy	+172	New	+$8.91K	﹤0.01%	1437
2017 Q1	–	Sell	-35	Closed	-$3K	–	836
2016 Q4	$3K	Hold	35	–	–	﹤0.01%	554
2016 Q3	$2K	Hold	35	–	–	﹤0.01%	609
2016 Q2	$1K	Buy	+35	New	+$1.46K	﹤0.01%	622

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Allworth Financial's EGRX Position: Q4 2022 in Review

Allworth Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 6 shares.

Allworth Financial first reported a position in EGRX in Q2 2016 and held it in 6 quarters. The position peaked at $9K in Q1 2022. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

Allworth Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Allworth Financial sold 6 Eagle Pharmaceuticals, Inc. shares in Q4 2022.
Allworth Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 6 quarters.
Allworth Financial's Eagle Pharmaceuticals, Inc. position peaked at $9K in Q1 2022.
152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Allworth Financial's 13F filing for Q4 2022, filed 13 Jan 2023.